Why the study?
Does a novel risk assessment model improve the stratification of cancer-associated thrombosis risk compared to the original Khorana Score in patients with cancer?
Does a novel risk assessment model improve the stratification of cancer-associated thrombosis risk compared to the original Khorana Score in patients with cancer?
A novel risk assessment model improves upon the original Khorana Score by better stratifying patients with cancer into high- and low-risk groups for venous thromboembolism at 6 months.
Answers are grounded in this paper and cite their sources.
May support refined VTE stratification in cancer; leaves open need for prospective validation before guiding prophylaxis.
The novel RAM stratified patients with cancer into a high-risk group with 8%-10% cumulative incidence of VTE and 7% PE/LE-DVT at 6 months (v 3% and 2%, respectively, in the low-risk group). The model had improved performance over the original KS and doubled the number of VTE events in the high-risk stratum. We encourage additional external validation from prospective studies.[Media: see text].
No takes yet. Share an insight, caveat, or question.
Li et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: